Subclinical time span of inflammatory bowel disease in patients with primary sclerosing cholangitis
The DOI matches its Crossref record.
Abstract
PURPOSE: This study is designed to describe colonic histology in patients with primary sclerosing cholangitis (PSC) without clinical symptoms of inflammatory bowel disease (IBD) and to do a follow-up study of these patients to find the time span from first detection of histologic signs until development of clinical symptoms of IBD. METHODS: In a cohort of 76 patients with PSC treated at Huddinge University Hospital, 11 patients did not have any clinical symptoms of IBD at the time of PSC diagnosis. Nine of these patients underwent diagnostic colonoscopy with multiple biopsies. RESULTS: In the group of nine PSC patients, without clinical signs of IBD undergoing colonoscopy, histologic signs of IBD were found in seven patients (6 ulcerative colitis and 1 Crohn's disease). Among them one had dysplasia, and another had epithelial changes probably positive for dysplasia. Two other patients had histologic signs of inflammation, however, not fully compatible with IBD. Three of 11 patients developed clinical symptoms of IBD after one, three, and seven years of follow-up since diagnostic colonoscopy. CONCLUSIONS: In patients with PSC, histologic signs of IBD, including premalignant changes, may precede development of clinical symptoms of IBD by as much as seven years. This indicates that IBD onset may have a substantial subclinical phase of IBD far longer than previously appreciated. This finding may be of clinical importance because underestimation of disease duration may delay inclusion of PSC patients with extensive colitis in colonoscopic surveillance programs. The subclinical phase may also allow the studies of early pathogenesis in vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Silverberg, M. S., Satsangi, J., Ahmad, T., Arnott, I. D., Bernstein, C. N., Brant, S. R., Caprilli, R., Colombel, J.-F., Gasche, C., Geboes, K., et al. (2005) · Canadian Journal of Gastroenterology · doi:10.1155/2005/269076 · Cited by 3,409
PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis
Loftus, E. V., Harewood, G. C., Loftus, C. G., Tremaine, W. J., Harmsen, W. S., Zinsmeister, A. R., Jewell, D. A., & Sandborn, W. J. (2005) · Gut · doi:10.1136/gut.2004.046615 · Cited by 777
EASL Clinical Practice Guidelines on sclerosing cholangitis
Chazouilleres, O., Beuers, U., Bergquist, A., Karlsen, T. H., Levy, C., Samyn, M., Schramm, C., & Trauner, M. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.05.011 · Cited by 419
High lifetime risk of cancer in primary sclerosing cholangitis
Claessen, M. M. H., Vleggaar, F. P., Tytgat, K. M. A. J., Siersema, P. D., & van Buuren, H. R. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2008.08.013 · Cited by 412
Cancer surveillance in patients with primary sclerosing cholangitis
Razumilava, N., Gores, G. J., & Lindor, K. D. (2011) · Hepatology · doi:10.1002/hep.24570 · Cited by 292
Primary sclerosing cholangitis is associated with a distinct phenotype of inflammatory bowel disease
Boonstra, K., van Erpecum, K. J., van Nieuwkerk, K. M. J., Drenth, J. P. H., Poen, A. C., Witteman, B. J. M., Tuynman, H. A. R. E., Beuers, U., & Ponsioen, C. Y. (2012) · Inflammatory Bowel Diseases · doi:10.1002/ibd.22938 · Cited by 262
Aabakken, L., Karlsen, T., Albert, J., Arvanitakis, M., Chazouilleres, O., Dumonceau, J.-M., Färkkilä, M., Fickert, P., Hirschfield, G., Laghi, A., et al. (2017) · Endoscopy · doi:10.1055/s-0043-107029 · Cited by 255
Distinctive inflammatory bowel disease phenotype in primary sclerosing cholangitis
Vries, A. B. D. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i6.1956 · Cited by 253
Loftus, E. V., Aguilar, H. I., Sandborn, W. J., Tremaine, W. J., Krom, R. A., Zinsmeister, A. R., Graziadei, I. W., & Wiesner, R. H. (1998) · Hepatology · doi:10.1002/hep.510270308 · Cited by 204
Hepatopancreatobiliary manifestations and complications associated with inflammatory bowel disease
Navaneethan, U., & Shen, B. (2010) · Inflammatory Bowel Diseases · doi:10.1002/ibd.21219 · Cited by 201
“patients died during follow-up before developing any obvious IBD-associated symptoms and 3 patients later developed clinical symptoms of IBD.(16) Similarly, a pediatric study showed that 11% of PSC patients had asymptomatic IBD at the time of PSC diagnosis.”
ResultAbnormal hepatic biochemistries in patients with inflammatory bowel disease
Mendes, F. D., Levy, C., Enders, F. B., Loftus, E. V., Angulo, P., & Lindor, K. D. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00947.x · Cited by 147
Shah, S. C., ten Hove, J. R., Castaneda, D., Palmela, C., Mooiweer, E., Colombel, J.-F., Harpaz, N., Ullman, T. A., van Bodegraven, A. A., Jansen, J. M., et al. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.01.023 · Cited by 109
Aabakken, L., Karlsen, T. H., Albert, J., Arvanitakis, M., Chazouilleres, O., Dumonceau, J.-M., Färkkilä, M., Fickert, P., Hirschfield, G. M., Laghi, A., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.02.013 · Cited by 107
The IBD and PSC phenotypes of PSC-IBD
Ricciuto, A., Kamath, B. M., & Griffiths, A. M. (2018) · Current Gastroenterology Reports · doi:10.1007/s11894-018-0620-2 · Cited by 94
Metadata
- Authors
- Broomé, U., Löfberg, R., Lundqvist, K., & Veress, B.
- Venue
- Diseases of the Colon & Rectum
- Published
- 1995-12
- Volume
- 38
- Issue
- 12
- Pages
- 1301-1305
- ISSN
- 0012-3706 (ISSN-L)
- OpenAlex
- W1973291763
- Cited by
- 106
- References
- 0
- FWCI
- 1.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.